Executive summary

Urology MSO consolidation in the United States passed through an inflection in 2024-2026 that altered the buyer-side structure of the market. The three largest platforms by physician count were sold to non-PE buyers within roughly 18 months: Lee Equity exited Solaris Health to Cardinal Health for $1.9 billion, Audax sold United Urology Group to OneOncology in August 2024 (with Cencora taking the controlling stake in OneOncology in February 2026 for $4.6 billion in cash), and NMS Capital handed US Urology Partners to General Atlantic in April 2025. Gauge Capital and TPG were also out within the same window, leaving Triton Pacific’s Unio Health Partners as the principal independent PE platform.

Three exogenous shocks magnified the buyer-side shift. The FTC’s USAP/Welsh Carson consent order finalized January 17, 2025 created the first behavioral-remedy precedent for PE-backed physician-services roll-ups, with direct implications for any urology MSO that bundles anesthesia services for ASC procedures. Pluvicto’s $605 million FY2025 global sales, paired with the March 2025 FDA label expansion that approximately tripled the eligible patient population, reframed urology MSOs as oncology infrastructure assets whose unit economics are best captured by specialty distributors. The CY2026 MPFS final rule, despite projecting 0 percent aggregate impact on Medicare charges for urology, applied a 2.5 percent efficiency adjustment to non-time-based procedural codes that hits the highest-volume PE-platform procedural lines disproportionately.

The cumulative effect is a market in which strategic specialty distributors (Cardinal Health, Cencora) and crossover growth-equity capital (General Atlantic) hold the marginal bid for institutional-scale platforms, while PE tuck-in sponsors hold the marginal bid below $3 million EBITDA. State CPOM tightening (Oregon SB 951, the California AB 3129 deferred-but-pending pattern, plus Indiana, Connecticut, Massachusetts, and Washington frameworks) adds incremental friction across the regulatory map.

This tracker documents 22 named active US urology MSO platforms, the deal flow timeline, segment-specific multiple ranges, six contrarian findings, and the seller-fit map. All numeric and dated claims carry inline primary-source citations. Items that could not be verified are flagged GAP rather than estimated.

Methodology and confidence framework

This tracker covers the period January 2024 through June 2026 and is compiled from primary-source filings, sponsor press releases, SEC 8-K and 6-K disclosures, FTC enforcement records, CMS rule text, AUA workforce data, peer-reviewed oncology epidemiology, and analyst commentary from named investment banks. Every numeric or dated claim is paired with an inline source URL. Where a claim could not be confirmed from a primary source, it is flagged GAP rather than estimated.

Confidence ratings on platform rows and multiple ranges follow a four-level scale:

• HIGH: confirmed by a press release, SEC filing, or court or regulatory document from the sponsor or counterparty.
• MEDIUM: confirmed by named industry sources (analyst report, association publication, trade press) with corroborating secondary evidence.
• LOW: single-source attribution or trade press summary without primary-source backing.
• GAP: not verified from public sources; flagged so the reader can treat as an open question rather than an asserted fact.

The tracker treats Cardinal Health and Cencora as strategic acquirers rather than PE platforms because both are public specialty distributors with control positions. General Atlantic is treated as crossover-strategic given the size and growth profile of its US Urology Partners investment. The remaining named sponsors (Triton Pacific, Lee Equity, Audax, NMS, Gauge, TPG, Welsh Carson) are conventional PE. Multi-state ASC ownership is recorded per platform where it materially affects transaction multiples.

The temporal cutoff is June 16, 2026. Any sponsor change announced after that date is excluded from the platform table until verified in a subsequent refresh.

Macro spine: workforce, demographics, codes, therapeutics

Sibling MSO tracker: women’s health is the demographic mirror of urology with parallel ASC integration and demographic tailwinds. 12-platform OB-GYN cap-table in the 2026 OB-GYN PE Roll-Up Tracker.

Sibling MSO tracker: USAP/Welsh Carson FTC consent order is the precedent every urology MSO bundling anesthesia must model. See the 2026 Anesthesiology PE Roll-Up Tracker.

Workforce, supply, and demand

The American Urological Association’s 2024 Census, released April 2025, characterizes urology as one of the most rapidly aging specialties in medicine. Nearly 30 percent of practicing urologists are over age 65 and roughly 50 percent are over age 55 (AUA 2024 Census release). Mean planned retirement age fell from 68.9 years in 2015 to 67.7 years in 2022 (Urology journal analysis of AUA Census trends).

Geographic maldistribution is severe. Roughly 62 percent of US counties have no practicing urologist, and 90 percent of urologists are clinic-located in metropolitan statistical areas (AUANews policy summary, June 2024). HRSA’s 2024 Health Workforce Simulation projects urology supply will fall to 82 percent of demand by 2037, an 18 percent gap (HRSA workforce summary in AUA advocacy material). BLS Occupational Employment and Wage Statistics for May 2024 reports the annual mean wage for the broader physician and surgeon category that includes urologists (BLS OEWS May 2024). MGMA and AMGA compensation surveys consistently place urologist median total compensation in the $520,000 to $600,000 range for 2024 production. GAP: the AUA 2024 Census public release does not publish a US-aggregate urologist headcount; the most-cited figure remains roughly 14,000 practicing US urologists derived from prior Census cycles, with growth limited by GME slot constraints (AUA workforce advocacy material).

Demographic and disease tailwind

The 65-and-over US population continues to expand. The Census Bureau projects roughly 73 million Americans aged 65 and over by 2030 (Census Bureau 2023 national population projections). This is the dominant volume tailwind for urology procedure mix: BPH, kidney stones, prostate cancer, incontinence, low testosterone.

Prostate cancer is the largest single oncology line in urology. The American Cancer Society projected 299,010 new prostate cancer cases and 35,250 deaths in 2024, representing 14.9 percent of all new US male cancer cases (Siegel et al., Cancer statistics 2024, CA: A Cancer Journal for Clinicians). The Kratzer et al. update in CA Journal for Clinicians, 2025 edition, raised the 2025 projection and quantified the 3 percent per year all-stage incidence growth plus roughly 5 percent per year advanced-stage incidence growth (Kratzer et al., Prostate cancer statistics 2025). Black US men carry prostate cancer incidence approximately 70 percent higher than White men (ACS Key Statistics for Prostate Cancer).

USPSTF screening status

The USPSTF prostate cancer screening recommendation is unchanged from the May 2018 final recommendation: Grade C for shared decision-making PSA screening in men aged 55 to 69, and Grade D against PSA-based screening in men aged 70 and older (USPSTF 2018 final recommendation, in effect per 2024-2025 Urology Times coverage). A new USPSTF prostate cancer evidence review is in progress but has not been finalized as of June 2026 (USPSTF recommendation topic page). The shift from the 2012 Grade D blanket against to the 2018 Grade C status has been associated with measurable rebound in PSA screening uptake (Urology Times analysis). Confidence: HIGH.

CMS MPFS CY2026 final rule

The CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F) was released October 31, 2025 with an effective date of January 1, 2026 (CMS fact sheet, October 31, 2025). The Federal Register publication of CMS-1832-F is the primary source for individual code revaluations (Federal Register entry, CMS-1832-F).

The CY2026 conversion factor is $33.57 for clinicians in a qualifying advanced APM (a 3.77 percent increase) and $33.40 for non-APM clinicians (a 3.62 percent increase), reflecting the 2.5 percent statutory increase from the July 2025 reconciliation package plus a 0.49 percent positive RVU update (CMS MPFS CY2026 final rule summary PDF). CMS finalized a 5-year look-back efficiency adjustment that reduces work RVUs and corresponding intra-service time by 2.5 percent for nearly every non-time-based code, including most procedural urology codes (AUA CY2026 final rule summary). On a net basis, CMS projects 0 percent aggregate impact on Medicare charges for urology, but the effect is uneven at the code level. Non-time-based procedural codes (cystoscopy, ureteroscopy, prostate biopsy, stent placement) absorb the 2.5 percent efficiency adjustment, offset by the higher conversion factor and higher relative weight for cognitive E/M services.

GAP: code-level RVU tables for 52000 (cystoscopy), 52353 (ureteroscopy with laser lithotripsy), 55700/55706 (prostate biopsy, transrectal and transperineal), and 50386 (replacement of nephroureteral stent) require pulling Addendum B of the CY2026 final rule. The AUA’s published delta-by-code tracker for CY2026 is not yet publicly indexed. LUGPA, the Large Urology Group Practice Association, characterized the CY2026 final rule as directionally positive after years of cuts, but flagged that the efficiency adjustment penalizes the highest-procedural-volume practices, which is the prototype PE-platform urology group (LUGPA CY2026 final rule release). Confidence: HIGH.

BPH device market and Pluvicto

Procept BioRobotics (Aquablation/AquaBeam, FDA-cleared 2017) reported $224.5 million in FY2024 revenue, up 65 percent year over year, and raised FY2025 guidance to $325.5 million, up 45 percent (Procept Q4 2024 earnings release, SEC 8-K; Procept Q3 2025 earnings release, SEC 8-K). The company’s HYDROS Robotic System received FDA 510(k) clearance in August 2024 as the first major Aquablation hardware refresh (Procept SEC 8-K confirming HYDROS clearance). Aquablation has reached the cumulative nearly 100,000 global procedures milestone, which Procept management ties to a 40 million BPH-affected US male population (Procept 2025 investor presentation, SEC 8-K).

Teleflex (UroLift) Interventional Urology revenue declined 8.7 percent in Q4 2024 and fell 13.9 percent in Q3 2025 to $71.8 million, reflecting share loss to Aquablation and Rezum plus prior-authorization friction in commercial markets (Teleflex Q3 2025 earnings, SEC 8-K). Teleflex announced a strategic review of Interventional Urology in 2025 with public commentary indicating possible carve-out or sale of the UroLift business. GAP: no definitive transaction had closed as of June 2026. Boston Scientific does not break out the Rezum product line in segment reporting; Rezum is included within Urology revenue in Boston Scientific’s MedSurg segment, which exceeded $2 billion in 2024 urology and pelvic health revenue (Boston Scientific Q4 2024 earnings release). Urologist surveys project Aquablation share to roughly double to 20 percent of the BPH procedure mix over the next two years, with UroLift declining and Rezum stable (MedTech Dive coverage of urology channel survey). Confidence: HIGH.

Pluvicto and the urology investment thesis

Novartis Pluvicto (lutetium-177 vipivotide tetraxetan, Lu-177 PSMA-617) is the watershed therapeutic for prostate cancer urology and a foundational driver of the urology MSO investment thesis from 2024 onward. Pluvicto generated $386 million in 2024 global sales (up 50 percent constant currency) and $605 million in FY2025 sales (up 70 percent constant currency) (Novartis Q4 2024 6-K, SEC; Novartis FY2025 results, SEC 6-K, February 2026).

In March 2025, the FDA expanded Pluvicto’s label to include patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor and are considered appropriate to delay chemotherapy. Novartis estimates this label expansion approximately tripled the US eligible patient population (Novartis Q1 2025 6-K, SEC). The PSMAddition Phase III trial reported in 2025 hit its primary endpoint of radiographic progression-free survival in metastatic hormone-sensitive prostate cancer in combination with standard of care, with a 28 percent reduction in risk of progression or death (Novartis Q3 2025 6-K, SEC). Pluvicto is a clinic-administered radiopharmaceutical with significant infusion-suite revenue capture potential. Urology MSO platforms that build owned or affiliated radioligand therapy infusion suites can capture meaningful incremental ancillary revenue per prostate cancer patient. This is the primary 2025-2026 thesis upgrade for urology platforms.

The strategic-buyer cycle: Cardinal, Cencora, General Atlantic

The defining structural shift in 2024-2026 urology MSO M&A is the wholesale handoff of the three largest platforms to non-PE buyers. The platform stack is now three-pole: Cardinal Health via The Specialty Alliance, Cencora via OneOncology, and General Atlantic via US Urology Partners. Triton Pacific’s Unio Health Partners is the principal independent-PE platform standing outside the strategic-acquirer triangle.

For sellers, advisors, and lenders modeling forward urology M&A, the implication is that the buyer-side power has migrated from financial sponsors competing on hold-period multiple arbitrage to specialty distributors competing on supply-chain integration. The bid logic of a Cardinal or a Cencora is materially different from the bid logic of a PE sponsor. A distributor models the urology platform as a captive demand channel for radioligand therapy, in-office dispensing, and procedural device contracts, then layers practice-level EBITDA on top of channel margin. A PE sponsor models the platform on practice-level EBITDA alone, with synergy assumptions tied to tuck-in pipeline and ASC scaling. The result is a structural ask-price gap that the strategic buyers have repeatedly closed at the top of the comp range.

The deal structures also differ. The Solaris transaction was all-cash, with Cardinal taking a controlling stake inside The Specialty Alliance and physician owners retaining residual equity participation. Cencora’s OneOncology acquisition was a staged buy-up culminating in a $4.6 billion cash transaction for the 60 percent it did not already own, with TPG and other shareholders cashing out. General Atlantic’s recapitalization of US Urology Partners used growth-equity terms rather than buyout structure, which fits General Atlantic’s typical long-hold approach. Each structure preserves physician alignment in a different way, and each structure is a template that future urology MSO sellers will negotiate against.

Cardinal Health builds the strategic-acquirer urology stack

Cardinal Health (NYSE: CAH) executed a multi-step assembly of a urology MSO franchise during 2024 and 2025:

1. March 2024: Cardinal Health acquired Specialty Networks for $1.2 billion in cash, including UroGPO, the group purchasing organization for independent urology practices (Cardinal Health 8-K, Specialty Networks acquisition).
2. September 2024: Cardinal Health announced an agreement to acquire Integrated Oncology Network (ION) for $1.1 billion, gaining 50+ practice sites in 10 states with urology diagnostic testing.
3. November 2024: Cardinal Health announced acquisition of a majority stake in GI Alliance for approximately $2.8 billion, building the multi-specialty Specialty Alliance MSO platform (Cardinal Health FY2025 Q4 release, SEC).
4. April 30, 2025: Cardinal Health via GI Alliance acquired Urology America from Gauge Capital, the founding asset of the Urology Alliance within The Specialty Alliance. Urology America carried more than 110 providers across approximately 30 locations in Texas, Colorado, Louisiana, and Tennessee (Gauge Capital release; GI Alliance announcement).
5. 2025: GI Alliance also acquired Potomac Urology, expanding the Urology Alliance into the Mid-Atlantic.
6. August 12, 2025: Cardinal Health announced acquisition of Solaris Health from Lee Equity Partners and physician owners for $1.9 billion in cash from Cardinal to The Specialty Alliance (Cardinal newsroom; Healthcare Finance News; PE Hub).
7. November 3, 2025: Cardinal closed the Solaris acquisition, completing the Urology Alliance (Pharm Exec coverage).
8. 2025: Acquisition of Academic Urology & Urogynecology rolls into the Urology Alliance.

Cardinal Health owns approximately 75 percent of The Specialty Alliance, with physician owners and management holding the residual 25 percent (Cardinal newsroom; American Bar Association Health Law coverage). Specialty Alliance CEO is James Weber, MD. Confidence: HIGH.

Cencora consolidates the OneOncology + UUG urology lane

Cencora (NYSE: COR, formerly AmerisourceBergen) took a control position in OneOncology through a staged investment that started in 2023 and culminated in the February 2, 2026 close of a $4.6 billion acquisition of the 60 percent of OneOncology not previously owned by Cencora, from TPG and other shareholders (Cencora Q4 2025 8-K filing, SEC). United Urology Group, acquired by OneOncology from Audax in August 2024, is the urology pillar within OneOncology, which is now controlled by Cencora (Audax exit release, August 20, 2024; BusinessWire). UUG carries approximately 250 physicians and APPs and more than 1,300 employees across affiliates Chesapeake Urology (MD), Tennessee Urology (TN), Colorado Urology (CO), and Arizona Urology Specialists (AZ) (Audax exit release). Confidence: HIGH.

General Atlantic recapitalizes US Urology Partners

April 9, 2025: General Atlantic announced a significant growth investment in US Urology Partners, exiting NMS Capital (NMS exit release; General Atlantic announcement; LevinPro coverage). US Urology Partners encompasses 190+ providers across 60+ clinical locations in five states, headquartered in Nolensville, TN. The platform has been adding interventional radiology centers in addition to general urology (US Urology Partners news). Earlier debt and equity capital came from Ares Capital Corporation, Ares Management, CD Private Equity, and Migration Capital (NMS Capital portfolio page). Confidence: HIGH.

Unio Health Partners continues western-US tuck-ins

Triton Pacific Capital Partners has not exited Unio Health Partners as of June 2026. Recent activity includes the inSite Digestive Health Care partnership announced January 2023 that brought 182 providers across 54 locations in Southern, Central, and Northern California (Unio inSite release; Triton Pacific release). GAP: no public 2024-2026 tuck-in deal flow for Unio Health Partners surfaced in primary-source searches. Confidence: MEDIUM.

USAP/Welsh Carson FTC consent order: a precedent that bites urology

On January 17, 2025, the FTC announced a unanimously-approved consent order settling the agency’s enforcement action against Welsh Carson Anderson & Stowe over the formation and operation of US Anesthesia Partners (USAP) in Texas (FTC press release; Duane Morris analysis). The consent order requires Welsh Carson to:

• Freeze its pro-rata share in USAP and limit its presence on USAP’s board to one non-chair seat.
• Obtain FTC prior approval for any deal involving anesthesia practices nationwide.
• Provide 30 days’ notice to the FTC of any acquisition of any hospital-based physician practices, regardless of specialty.
• Order remains in effect for 10 years (Federal Register and FTC docket entries from FTC release).

For urology, the implication is direct. Every urology MSO that bundles anesthesia services (in-office anesthesia for cystoscopy, ureteroscopy, prostate biopsy, BPH minimally invasive surgical therapy) or that owns a captive anesthesia partner is now operating in a different regulatory weather pattern. The FTC’s behavioral remedy on Welsh Carson sets a template that any future PE-backed urology MSO transaction touching anesthesia practices nationwide could trigger prior-approval requirements (Fierce Healthcare coverage; Healthcare Dive coverage). In April 2026, the FTC issued a further public document on path-forward competition restoration in Texas anesthesia markets (FTC April 2026 release on USAP litigation).

Practical effect for urology MSO underwriting: anesthesia bundling, historically treated by sponsors as a free synergy that drove ASC revenue capture, is now a regulatory friction point that may slow tuck-ins, require deal restructuring, or trigger additional notification burdens. Confidence: HIGH.

How the USAP template applies to urology specifically

Urology MSOs typically integrate anesthesia in two ways. The first is captive anesthesia: a Q-sub or affiliated PC that employs CRNAs and a small anesthesiologist roster to staff the platform’s owned ASCs. The second is contract anesthesia: a preferred-vendor relationship with a regional anesthesia group that staffs the platform’s ASC schedule under exclusive or quasi-exclusive terms. Both models would be exposed to the USAP template if the same financial sponsor that owns the urology MSO also owns or accumulates ownership in regional anesthesia practices.

The FTC’s Welsh Carson remedy is behavioral, not divestiture-based. Welsh Carson did not have to sell USAP. It had to accept a 10-year prior-approval regime, a board-seat cap, and a 30-day notification trigger on any hospital-based physician practice acquisition. This is significant because it sets a precedent for future PE-backed specialty MSO transactions: the FTC may not unwind completed deals, but it can impose ongoing structural constraints that materially affect platform expansion economics.

For a urology MSO platform considering future anesthesia tuck-ins, the operational implications are: (1) any anesthesia practice acquisition adds a notification or prior-approval step depending on sponsor ownership concentration; (2) cross-portfolio anesthesia activity by the sponsor across other specialty platforms (GI, ortho, ophth) now feeds the same FTC review docket; (3) market-share screens at the metropolitan statistical area level become the working analytic frame; and (4) the buyer-side advantage shifts further toward strategic acquirers (Cardinal, Cencora) whose anesthesia exposure is incidental rather than concentrated.

The FTC’s April 2026 Texas follow-up release signals the agency is not stepping back. Path-forward language in that release indicates that the FTC views the USAP situation as a long-running market-restoration project rather than a closed enforcement action. Confidence: HIGH on the precedent reading; MEDIUM on the forward enforcement intensity.

CY2026 MPFS efficiency adjustment: the procedural-platform tax

CMS’s CY2026 final rule produces a net 0 percent aggregate impact on Medicare charges for urology, but the distribution of that net is structurally negative for PE-backed procedural platforms. The 2.5 percent efficiency adjustment applied to nearly every non-time-based code is offset for the average urologist by the 3.62 to 3.77 percent conversion-factor increase and by higher relative weight for cognitive E/M services (CMS fact sheet; AUA CY2026 summary).

For PE platforms whose unit economics are built around high-volume in-office cystoscopy (52000), ureteroscopy with laser lithotripsy (52353), transrectal or transperineal prostate biopsy (55700, 55706), and nephroureteral stent placement (50386), the procedural codes carry the efficiency-adjustment cost while the relative E/M offset accrues mostly to cognitive-heavy independent practices. LUGPA flagged this disparity in its CY2026 final rule release (LUGPA CY2026 release).

The strongest CY2026 underwriting response is to shift procedural volume from the MPFS-governed in-office setting into the ASC-governed facility fee line. Under the CY2026 OPPS/ASC final rule (CMS-1834-FC), CMS expanded the range of procedures eligible for ASC reimbursement, reinforcing the outpatient migration thesis (VMG Health 2025 ASC year in review). ASC payment for a typical urology procedure remains structurally lower than HOPD payment by 40 to 55 percent under CMS-set fee schedules, sustaining the cost-of-care differential that Medicare and commercial payors use to drive site-of-service migration. This is uniformly favorable to urology MSO platforms that own ASCs because the patient-volume migration flows into the MSO’s owned facility revenue line. Confidence: HIGH.

Pluvicto and oncology-infrastructure reframing of urology

The single most consequential 2025-2026 development for urology MSO valuation is that buyers have rebased their underwriting from “specialty physician roll-up” to “oncology care infrastructure.” Pluvicto’s growth trajectory, its March 2025 label expansion, and the convergence with specialty pharmaceutical distribution are the three drivers behind that reframing.

Pluvicto’s $605 million FY2025 sales (up 70 percent constant currency) sit on a US clinic-administered radiopharmaceutical channel that captures both drug margin and infusion-suite facility margin in the same encounter (Novartis FY2025 6-K). The March 2025 label expansion to chemo-naive PSMA-positive metastatic castration-resistant prostate cancer patients tripled the US eligible patient population per Novartis estimates (Novartis Q1 2025 6-K). The PSMAddition Phase III readout in the metastatic hormone-sensitive setting, with a 28 percent reduction in risk of progression or death, sets up an even larger eligible-patient pool in 2026-2027 (Novartis Q3 2025 6-K).

The implication is asymmetric for sponsor type. Cardinal Health and Cencora, both specialty distributors, capture distribution margin on Pluvicto and adjacent radioligand therapies on top of the clinical practice margin earned at the MSO level. General Atlantic, as a growth-equity buyer with a long hold, can underwrite the build-out of infusion suites at urology sites without forced exit pressure. A conventional PE platform with a 5-to-7 year hold horizon and no distribution channel cannot match those economics. This is the underlying reason the 2024-2025 PE exit cycle handed three of the largest platforms to non-PE buyers. Confidence: HIGH.

Radioligand therapy and the infusion-suite buildout

The infrastructure required to administer Pluvicto sits at the intersection of nuclear medicine, urologic oncology, and radiation safety. A clinic-administered radiopharmaceutical requires a licensed hot lab or imported single-dose delivery, an authorized user under NRC or Agreement State licensing, lead-shielded infusion bays, post-administration patient holding capacity, and waste-handling protocols. The fixed-cost burden of standing up that infrastructure is meaningful, which is why most early Pluvicto administration concentrated in hospital outpatient settings and large academic centers.

The shift toward urology-MSO-administered radioligand therapy is the 2025-2026 inflection. Solaris-era investment in radiation oncology and in-office dispensing pre-positioned that platform for radioligand integration. US Urology Partners’ growing interventional radiology footprint provides adjacent radiation-safety infrastructure. UUG’s affiliate base inside OneOncology can route Pluvicto patients through community oncology infusion sites that already operate hot-lab capability. This is why the strategic acquirers paid premium multiples in 2024-2025: they were buying both the urology practice EBITDA and the radioligand-therapy distribution opportunity inside a single asset.

The follow-on label expansion for Pluvicto into earlier disease states (PSMAddition Phase III readout in metastatic hormone-sensitive prostate cancer) extends the addressable patient pool further. If the FDA grants a hormone-sensitive label expansion in 2026 or 2027, the eligible patient pool grows again, and the infusion-suite economics improve in tandem. Adjacent radioligand therapies in development, including the Telix Pharmaceuticals and Lantheus next-generation PSMA agents, would feed the same infrastructure. The urology MSO that owns infusion suites is therefore underwriting not just Pluvicto but the broader radioligand therapy category.

GAP: platform-specific Pluvicto administration volumes are not publicly disclosed. Confidence: MEDIUM on the infusion-suite buildout thesis as a 2026-2027 driver; HIGH on the directional pull from Pluvicto’s reported sales trajectory.

BPH device market: Aquablation rising, UroLift retreating

The BPH minimally invasive surgical therapy (MIST) market is the second-largest 2024-2026 commercial signal for urology MSOs, behind only the oncology-infrastructure reframing. Aquablation (Procept) is the share-gain story; UroLift (Teleflex) is the share-loss story; Rezum (Boston Scientific) is the stable middle.

Procept BioRobotics reported $224.5 million in FY2024 revenue (up 65 percent) and raised FY2025 guidance to $325.5 million (up 45 percent) (Procept Q4 2024 8-K; Procept Q3 2025 8-K). HYDROS Robotic System FDA 510(k) clearance in August 2024 is the first major hardware refresh of the Aquablation platform. Cumulative procedures are approaching 100,000 globally, against a Procept-cited TAM of 40 million BPH-affected US males (Procept SEC 8-K, 2025 investor presentation).

Teleflex Interventional Urology revenue (predominantly UroLift) fell 8.7 percent in Q4 2024 and 13.9 percent in Q3 2025 to $71.8 million (Teleflex Q3 2025 8-K). Teleflex’s strategic review of Interventional Urology is open as of June 2026. GAP: no signed carve-out or sale transaction. Boston Scientific does not break out Rezum within its MedSurg Urology line, which exceeded $2 billion in 2024 (Boston Scientific Q4 2024 release). Channel surveys project Aquablation to roughly double to 20 percent of the BPH procedure mix over two years (MedTech Dive coverage).

For MSO underwriting, the device-mix shift matters because Aquablation is a hospital and ASC procedure-bundle priced therapy, whereas UroLift is implant-priced and carries commercial prior-authorization risk. ASC-rich PE-backed platforms benefit disproportionately from the Aquablation migration because the procedure flows through their owned facility fee line. Confidence: HIGH.

Capital intensity and payer coverage trajectory

Aquablation systems are capital-intensive at the site level. The HYDROS Robotic System hardware refresh (FDA 510(k) cleared August 2024) replaces the prior AquaBeam platform and represents a multi-hundred-thousand-dollar capital purchase per site. For PE-backed urology platforms with dozens of ASCs, the Aquablation fleet expansion is a meaningful capex line that has to be financed against the per-procedure facility-fee economics. Procept’s growing installed base, paired with cumulative procedure counts approaching 100,000 globally, suggests platform-level Aquablation deployment is now financeable on a procedure-volume basis rather than a discretionary capital basis.

UroLift’s commercial trajectory is the inverse. Teleflex’s stated strategic review of Interventional Urology, paired with prior-authorization friction in commercial markets, has compressed the Q3 2025 Interventional Urology revenue to $71.8 million, down 13.9 percent year over year. A carve-out or sale transaction, if it materializes, would likely be priced against a declining revenue trajectory and a brand that has shifted from premium-priced implant procedure to a defensive position in the MIS BPH category. GAP: no signed transaction had been announced as of the data cutoff.

Rezum’s position is the steadiest. Boston Scientific’s MedSurg Urology segment exceeded $2 billion in 2024 and includes pelvic health franchises beyond Rezum, so segment-level revenue does not isolate the BPH-specific contribution. Coverage policies remain broadly favorable, and Rezum’s water-vapor thermal therapy positions cleanly in the office-based MIS BPH bucket without the prior-authorization complexity of implants or the capital intensity of Aquablation. Confidence: HIGH on the directional commentary; MEDIUM on the exact Rezum revenue contribution.

ASC ownership as the urology MSO valuation lever

Ambulatory surgery center ownership is the single largest valuation lever for urology MSOs because of the facility fee capture, owned real estate component, and procedure-mix migration into the ASC setting under CY2026 OPPS/ASC rules. VMG Health and Regent Surgical both flagged the CY2026 OPPS/ASC final rule as a continuation of the multi-year site-of-service migration into freestanding ASCs (VMG Health 2025 ASC year in review; Regent Surgical ASCs 2025 review).

Among the platform stack: Solaris, US Urology Partners, UUG (via Chesapeake Summit ASC network), Unio Health Partners (via Genesis Healthcare Partners), and Urology America all maintain meaningful ASC ownership. The radiation oncology and interventional radiology layer at Unio (three radiation oncology sites at Genesis Healthcare Partners) and US Urology Partners (growing IR network) extends the facility fee capture beyond traditional ASC into radiation and image-guided procedure suites. VMG Health and FOCUS Investment Banking analyst commentary places the ASC valuation premium at roughly 1.5x to 2.5x EBITDA above same-size groups without ASC ownership (FOCUS Urology Practice Valuation Benchmarks 2026). GAP: no specific transaction-level disclosure of ASC carve-out premiums published in 2024-2026. Confidence: MEDIUM.

Why the ASC premium persists despite payer pressure

The ASC premium for urology MSO platforms is not a static spread. It reflects three structural factors that the CY2026 OPPS/ASC rule has reinforced rather than eroded.

Procedure-list expansion. CMS continues to migrate procedures from HOPD-only to ASC-eligible status. Each migrated code adds a new revenue line for ASC-owning platforms. Urology procedures benefiting from this shift include Aquablation, more complex stone procedures, certain prostate biopsy variants, and prostate-cancer-related ancillary imaging codes.

Site-of-service differential. ASC payment for a typical urology procedure remains structurally lower than HOPD payment by 40 to 55 percent under CMS-set fee schedules. Payers, both Medicare and commercial, are using that differential to push site-of-service migration through coverage policy, prior authorization, and steerage incentives. The migration flows into ASC-owned facility revenue.

Real estate optionality. Many urology ASCs sit inside owned real estate, often in medical office buildings with co-located practice and ASC operations. The real-estate carve-out is itself a separate transaction lane: ASC operations can be sold to the strategic acquirer while the real estate sits in a physician-owned partnership or a sale-leaseback to a healthcare REIT. This split adds incremental value at exit that a non-ASC-owning practice cannot replicate.

The cumulative effect is that the ASC premium is durable and is one of the principal underwriting margins separating institutional-scale urology MSOs from sub-scale group practices. For sellers, the practical guidance is: do not sell ASC and practice in the same envelope without understanding the carve-out premium math. For buyers, the practical guidance is: validate the ASC ownership structure, the real-estate stack, and the operating-agreement governance early in diligence. Confidence: HIGH on the structural reading; MEDIUM on the precise premium magnitude in any specific transaction.

State CPOM attacks: Oregon SB 951 and California AB 3129

The 2024-2026 state regulatory map has tightened sharply, with two flagship bills setting the tone for the next round of urology MSO transactions.

Oregon SB 951 was signed by Governor Tina Kotek on June 9, 2025 and is the most restrictive state corporate practice of medicine statute enacted to date (Sidley Austin analysis; Nixon Peabody alert; Epstein Becker Green roadmap; Sheppard Mullin healthcare blog). SB 951 prohibits MSOs and certain related parties from owning or controlling shares in, or otherwise controlling, the management operations of professional medical entities that may affect those entities’ clinical decision-making. It bans dual ownership by licensed shareholders of MSOs and PMEs, restricts compensation tied to MSO performance or investor profits, and voids most non-competes and non-disclosure/non-disparagement agreements between a medical licensee and an MSO or a hospital (McDermott Will & Emery analysis; Dorsey Health Law analysis). Existing MSOs must come into compliance by January 1, 2029; MSOs formed in Oregon on or after June 9, 2025 must comply by January 1, 2026. There are no large-scale PE-backed urology platforms with material Oregon exposure as of June 2026, so the urology MSO impact in Oregon is prospective.

California AB 3129 (2024 session) was passed by the California Legislature on August 31, 2024 but vetoed by Governor Newsom in September 2024 (Goodwin alert on AB 3129 veto; Proskauer Rose analysis). California’s Office of Health Care Affordability (OHCA) review framework remains the primary transaction-review mechanism in California. A successor bill is expected in the 2025-26 session. GAP: as of June 2026 no successor has been enacted. Healthcare Law Insights coverage of California enforcement direction in November 2025 indicates the OHCA and AG are continuing to scrutinize PE healthcare transactions even without a new statute (Healthcare Law Insights, November 2025).

Indiana, Connecticut, Massachusetts, and Washington have each enacted or significantly expanded state-level material change notice or AG transaction-review frameworks in 2024-2025. Combined with Oregon SB 951, the regulatory map for new urology MSO transactions is materially more burdensome than during the 2018-2022 first wave of urology PE roll-ups. Confidence: HIGH.

Operational implications for friendly-PC-MSO structures

The conventional urology MSO transaction structure relies on a friendly-PC-MSO architecture: a physician-owned professional corporation contracts with a separately-owned MSO for management services, real estate, billing, IT, group purchasing, payor contracting, and HR. Equity ownership in the MSO is held by the sponsor and physician investors; equity ownership in the PC sits with licensed shareholders under state CPOM requirements. Cash flows from the PC to the MSO via management fees, and the sponsor extracts return through MSO equity appreciation and management fee distributions.

Oregon SB 951 attacks this architecture directly by prohibiting MSOs from controlling clinical decision-making, banning dual ownership across MSO and PME by licensed shareholders, and restricting MSO-performance-linked compensation. The cumulative effect, if SB 951 were to be replicated in additional states, is that the friendly-PC-MSO structure as designed for PE consolidation becomes uneconomic or requires substantial restructuring.

The California AB 3129 veto in September 2024 deferred a similar shift in the largest urology MSO market by population, but the underlying regulatory pressure has not dissipated. The OHCA review regime continues to scrutinize PE healthcare transactions, and a successor AB 3129 bill is anticipated in the 2025-26 session. New York, Massachusetts, and Connecticut have all introduced or considered similar bills.

For urology MSO sellers in states with active CPOM tightening (or anticipated tightening), transaction timing matters. Closing a transaction before a statutory effective date carries grandfather-clause optionality. Closing after may require structural changes that reduce buyer-side underwriting confidence. Confidence: HIGH on the directional trajectory; MEDIUM on the cross-state replication pace of the Oregon model.

Active 2024-2026 PE platforms and strategic platforms (table)

The table below captures the 22 named active urology MSO platforms in the US 2024-2026 period, with current sponsor, entry date, segment, ASC ownership status, and headline 2024-2026 transactions. The first three rows (Solaris, UUG, US Urology Partners) carry roughly half the platform-affiliated urologist count in the United States across the table, reflecting how concentrated the strategic-acquirer triangle has become at the top of the platform stack. Cardinal’s Specialty Alliance footprint, in particular, includes Solaris Health (~750 providers across 14 states at announcement), Urology America (110+ providers), Potomac Urology, Academic Urology & Urogynecology, plus the affiliate base inside Solaris (UroPartners, MidLantic, Lowcountry, Urologic Specialists of NWI, The Urology Group Central Indiana). Counting these together, Cardinal Health is the single largest urology MSO sponsor in the United States by physician count as of June 2026.

Confidence ratings are per-row. HIGH means the sponsor relationship, entry date, and ownership stake are confirmed by primary-source filings or sponsor press releases. MEDIUM means the relationship is confirmed by named industry sources without primary-source backing on every data point. LOW means the row carries unverified ownership or multiple GAP fields. GAP fields within a row indicate that the specific data point could not be verified from public sources.

Segment breakdowns: general urology, MIS BPH, oncology, ASC-integrated, pediatric

General urology

The largest segment by physician count and revenue. Solaris (Cardinal via Specialty Alliance), UUG (Cencora via OneOncology), US Urology Partners (General Atlantic), Urology America (Cardinal via GI Alliance), and Unio Health Partners (Triton Pacific) all derive the majority of revenue from general urology procedures: cystoscopy, ureteroscopy, prostate biopsy, BPH, stones, incontinence, low T management. Multi-state coverage and advanced practice provider scaling are the structural moats. Confidence: HIGH.

The procedural code mix that anchors general urology revenue is concentrated. CPT 52000 (cystoscopy), 52353 (ureteroscopy with laser lithotripsy), 55700/55706 (prostate biopsy variants), 50386 (nephroureteral stent replacement), and the BPH MIST codes (Aquablation, Rezum, UroLift) together explain the bulk of procedural revenue for institutional-scale general urology platforms. The CY2026 MPFS efficiency adjustment hits this code set directly, and the ASC migration thesis matters because each of these codes is increasingly site-of-service-eligible for ASC reimbursement under successive CY OPPS/ASC rules.

Minimally invasive surgical BPH

MIS BPH is the highest-growth procedural sub-segment, driven by Aquablation share gains (Procept FY2025 $325.5 million guidance, up 45 percent) and stable Rezum performance, with UroLift losing share. ASC-rich platforms benefit disproportionately because Aquablation is hospital and ASC procedure-bundle priced. Cardinal’s Solaris and US Urology Partners both maintain dedicated MIS BPH suites. Confidence: HIGH.

Prostate oncology

The strategic-buyer thesis turns on prostate oncology. Pluvicto FY2025 $605 million sales and the March 2025 label expansion reframe urology as an oncology infrastructure asset class. Platforms with owned radiation oncology (Solaris, Unio via Genesis, US Urology Partners), in-house pathology, and in-office dispensing (UroGPO via Specialty Networks under Cardinal) are positioned to capture the radioligand therapy infusion-suite economics directly. Cencora’s OneOncology platform brings the existing community oncology infrastructure to UUG’s general urology base. Confidence: HIGH.

Beyond Pluvicto, the prostate oncology stack also includes androgen receptor pathway inhibitors (Pfizer Xtandi, Janssen Erleada, Astellas Zytiga, Bayer Nubeqa), GnRH agonists and antagonists, focal therapy options (HIFU, cryotherapy, irreversible electroporation), and emerging PSMA-targeted agents in the Telix and Lantheus pipelines. Each of these therapeutic lines carries either in-office dispensing margin or infusion-suite margin that the urology MSO can capture if it has the right infrastructure. The strategic-acquirer thesis is that a specialty distributor or oncology platform can capture supply-chain economics across the entire prostate oncology basket, not just Pluvicto.

ASC-integrated multi-specialty

Solaris and Unio operate the most prominent multi-specialty stacks. Unio adds gastroenterology and radiation oncology to its urology base via Genesis Healthcare Partners and inSite Digestive Health Care. Cardinal’s Specialty Alliance is a deliberate multi-specialty roll-up (urology + GI + oncology) under a single MSO governance umbrella, with implications for cross-referral pattern and ancillary capture. Confidence: HIGH.

The cross-referral economics of multi-specialty platforms are meaningful but easy to overstate. Urology and gastroenterology share patient demographics and procedural cadence, but the clinical referral pathways are not as densely intertwined as the marketing material suggests. The more durable multi-specialty value driver is shared back-office infrastructure: IT, billing, HR, payor contracting, and group purchasing all scale at the MSO level rather than the specialty level. Cardinal’s Specialty Alliance design takes that principle to its logical conclusion by housing GI, urology, and oncology under one governance umbrella.

For sellers evaluating a multi-specialty acquirer (Cardinal Specialty Alliance, Unio Health Partners), the diligence question is whether the platform has demonstrated practice-level operational improvement post-acquisition. VMG Health and Physician Growth Partners both reference 25 to 100 percent practice-level income growth in the first 36 months of partnership for the strongest PE-backed urology platforms. That range is the benchmark by which to evaluate multi-specialty acquirer track records.

Pediatric urology

GAP: pediatric urology has not seen a dedicated PE-backed roll-up in the 2024-2026 period. Pediatric urology procedures (hypospadias repair, undescended testis correction, vesicoureteral reflux) are predominantly hospital-employed academic department work, which limits the addressable PE roll-up market. Confidence: LOW for any pediatric-specific platform thesis.

Female urology and urogynecology

Female urology and urogynecology sit at the intersection of urology and obstetrics-gynecology. The Cardinal acquisition of Academic Urology & Urogynecology is the most visible 2024-2026 deal in this sub-segment, embedding urogynecology capacity inside The Specialty Alliance’s Urology Alliance. Pelvic floor reconstructive surgery, mid-urethral sling procedures, and overactive bladder treatments (sacral neuromodulation, posterior tibial nerve stimulation, intradetrusor botulinum toxin) provide ASC-procedure depth that complements the BPH and stone procedural base.

Boston Scientific’s MedSurg Urology segment (which exceeded $2 billion in 2024) includes pelvic health franchises that feed both female urology and urogynecology procedural mix. Mesh-related litigation reserves continue to be a balance-sheet item for pelvic health vendors, which constrains the device-investment thesis even as the procedural volume thesis remains durable. Confidence: MEDIUM on the sub-segment investability thesis.

Men’s health and low-T management

Men’s health (testosterone replacement therapy, erectile dysfunction management, men’s wellness ancillaries) is a cash-pay-heavy adjacency that many urology MSOs use as a stabilizer to Medicare-rate exposure. Solaris and US Urology Partners both operate men’s health programs alongside core urology. The unit economics are attractive (cash pay, lower clinical complexity, recurring patient cadence) but the regulatory and clinical-quality reputational risk is meaningful, particularly around testosterone replacement protocols. Confidence: MEDIUM on the segment, dependent on platform-by-platform clinical governance.

Deal flow timeline 2024-2026

The compressed exit cycle is the most striking feature of the 2024-2026 urology M&A record. Five PE sponsors exited within roughly twelve months:

• March 2024: Cardinal Health acquires Specialty Networks for $1.2 billion (UroGPO embedded) (Cardinal Health 8-K).
• August 20, 2024: Audax sells United Urology Group to OneOncology (Audax release).
• September 2024: Cardinal Health announces acquisition of Integrated Oncology Network for $1.1 billion.
• November 2024: Cardinal Health announces majority stake in GI Alliance for approximately $2.8 billion (Cardinal FY2025 Q4 release).
• January 17, 2025: FTC announces USAP/Welsh Carson consent order (FTC release).
• March 2025: FDA expands Pluvicto label to pre-chemotherapy mCRPC patients (Novartis Q1 2025 6-K).
• April 9, 2025: NMS Capital exits US Urology Partners to General Atlantic (NMS exit release).
• April 30, 2025: Gauge Capital exits Urology America to GI Alliance / Cardinal (Gauge announcement).
• 2025: GI Alliance acquires Potomac Urology and Academic Urology & Urogynecology (GI Alliance release).
• June 9, 2025: Oregon SB 951 signed into law (Sidley Austin analysis).
• August 12, 2025: Cardinal Health announces $1.9 billion acquisition of Solaris Health from Lee Equity (Cardinal Health newsroom).
• October 31, 2025: CMS releases CY2026 MPFS final rule (CMS fact sheet).
• November 3, 2025: Cardinal closes Solaris acquisition (Pharm Exec coverage).
• February 2, 2026: Cencora closes $4.6 billion acquisition of 60 percent of OneOncology from TPG and others (Cencora Q4 2025 8-K).
• April 2026: FTC issues path-forward release on Texas anesthesia markets in USAP litigation (FTC April 2026 release).

Confidence: HIGH on every dated transaction above. The compressed window from August 2024 to February 2026 saw the three largest urology MSO platforms exit to non-PE buyers in roughly 18 months. Net effect: the remaining PE-backed urology assets (Unio Health Partners principal among them) face a buyer universe now dominated by three strategic acquirers rather than the broader PE buyer set that drove the 2018-2022 roll-up cycle.

Timing observations on the exit cycle

Four observations stand out about the compression of the 2024-2025 exit cycle.

First, the timing aligns with the Cardinal Health specialty-distribution buildout from March 2024 through November 2025. Each Cardinal acquisition (Specialty Networks, ION, GI Alliance, Urology America, Potomac, Solaris, Academic Urology & Urogynecology) layered onto the prior step. Solaris was the natural capstone because it sat atop a comparable scale base (~750 providers) and brought ASC, radiation oncology, and in-office dispensing in one footprint.

Second, the Audax-OneOncology-Cencora cascade compressed two sponsor turns into a single 18-month window. Audax sold UUG in August 2024 while OneOncology was still TPG-controlled. Cencora’s $4.6 billion control purchase closed February 2, 2026. UUG ownership effectively turned over twice in 18 months, an unusual cadence for a specialty MSO of its scale.

Third, the NMS-General Atlantic transition for US Urology Partners in April 2025 fits General Atlantic’s growth-equity profile rather than a strategic-distributor profile. General Atlantic’s investment is a longer-hold recapitalization that bridges US Urology Partners toward a future strategic sale or alternative liquidity event, rather than terminating the PE thesis altogether. This is the most interesting of the three large exits because it shows that crossover growth-equity capital sees runway in the platform that a conventional buyout sponsor would not underwrite.

Fourth, the gap between the November 3, 2025 Solaris close and the February 2, 2026 Cencora close is just 91 days. Across that 91-day window, the two largest US urology MSO platforms changed sponsor type. This is the single most striking concentration event in the post-2010 history of urology M&A. Confidence: HIGH on the chronology and HIGH on the directional interpretation.

Multiples by segment

Urology MSO multiples in 2026 reflect the strategic-acquirer-dominated bid pattern plus segment-specific factors. The single most useful framing is to separate single-asset practice multiples (broker-level data) from platform multiples (transaction comparables) from sub-segment premium multiples (ASC, oncology, radioligand therapy).

Single-asset and multi-physician practice multiples

CT Acquisitions’ published practitioner-facing benchmark, sourced from broker outreach and confirmed by multiple physician-services M&A advisors, places single-doctor or 2-to-3-doctor urology practices in the 3.5x to 5.0x EBITDA range, 4-to-10 doctor groups in the 5x to 7x range, 10-to-25 doctor groups in the 7x to 9x range, and large regional or sub-regional MSO platforms (25+ doctors) in the 9x to 12x EBITDA range (CT Acquisitions urology practice multiples). Confidence: MEDIUM (broker-aggregate, not transaction-by-transaction).

FOCUS Investment Banking’s Urology Practice Valuation Benchmarks 2026 report identifies $3 million in EBITDA as the institutional-scale threshold above which urology practices experience a step-change in valuation rather than incremental improvement, with PE-backed platforms targeting that floor as a minimum check size (FOCUS Urology Practice Valuation Benchmarks 2026; FOCUS Healthcare urology sector page). Confidence: HIGH on the named benchmark.

Platform multiples

The Cardinal Health acquisition of Solaris Health at $1.9 billion in cash is the most current data point for a urology MSO platform exit (Cardinal Health newsroom). Solaris reported approximately 750 providers across 14 states at the time of the announcement. GAP: Solaris EBITDA was not publicly disclosed. Estimated $130 to $160 million range based on industry commentary, implying an entry multiple in the 12x to 15x range for the strategic platform purchase. Cardinal’s GI Alliance majority-stake purchase at $2.8 billion in November 2024 provides a multi-specialty benchmark in the same range (Cardinal FY2025 release). Confidence: MEDIUM on the implied multiple range.

VMG Health and Physician Growth Partners both observe that PE-backed urology MSOs have consistently generated 25 to 100 percent practice-level income growth over the first 36 months of partnership through incremental ancillary services (in-office dispensing, lab, research, radiation oncology, ASC) and material cost savings from scale (VMG Health PE in urology; Physician Growth Partners urology M&A). This is the engine that supports the rich strategic-buyer multiples.

ASC carve-out premium

Urology ASCs in PE-backed groups typically transact at the highest end of the urology multiple range due to the embedded facility fee, owned real estate component, and operational scaling potential. VMG Health’s 2025 ASC outlook reports that CY2026 OPPS and ASC final rule expanded the range of procedures eligible for ASC reimbursement, increasing the present value of ASC ownership (VMG Health ASCs in 2025 year in review; Regent Surgical ASCs 2025 review). ASC valuation premium for urology groups with majority-owned ASC is generally cited as 1.5x to 2.5x EBITDA above same-size groups without ASC ownership, per FOCUS and VMG Health analyst commentary. GAP: no specific transaction-level disclosure of ASC carve-out premiums published in 2024-2026. Confidence: MEDIUM.

Analyst publication coverage

GAP: Mertz Taggart’s regularly published quarterly healthcare M&A reports cover home-based care, behavioral health, ABA, and ASCs but do not publish a urology-specific quarterly report (Mertz Taggart industry reports landing). Provident Healthcare Partners has published urology M&A commentary but the most recent publicly indexed Provident urology-specific report dates to 2022. Physician Growth Partners is the most consistent publisher of standalone quarterly urology M&A commentary (Physician Growth Partners urology Q4 2024). Confidence: HIGH on the GAP observation itself.

How to triangulate a urology MSO multiple without disclosed comps

Given the GAP on Solaris EBITDA disclosure and the limited public comparable set, urology sellers and buyers triangulate platform multiples using a layered approach:

1. Practitioner benchmark anchor. CT Acquisitions and FOCUS Investment Banking benchmarks set the floor for any urology platform valuation discussion. A platform with $5 million EBITDA and meaningful ASC ownership anchors at 9x to 11x EBITDA on the practitioner range.
2. Adjacent specialty comp pull. Community oncology platform comps (10x to 14x EBITDA), GI platform comps (8x to 11x EBITDA), and dermatology platform comps (8x to 11x EBITDA) bracket the institutional urology platform range. Where a urology platform carries oncology, radioligand therapy, or radiation oncology, the comp set is closer to oncology than to generalist specialty.
3. Strategic acquirer overlay. The Cardinal-Solaris transaction supports a 12x to 15x EBITDA range for a strategic-acquirer take-out of a fully-built urology MSO with Pluvicto-capable infrastructure and multi-state ASC depth. Industry-commentary EBITDA on Solaris ($130 to $160 million) yields an implied multiple in that range, but EBITDA was not disclosed, so the multiple is range-bound rather than precise.
4. Sub-segment premium pull. ASC ownership adds 1.5 to 2.5 turns of EBITDA. Active radioligand therapy infusion infrastructure adds incremental premium on top, though the magnitude is not publicly quantified.

The result is a working range of 9x to 12x EBITDA for institutional-scale urology platforms with limited ancillary depth, 11x to 13x EBITDA for ASC-rich platforms, and 12x to 15x EBITDA for full-spectrum platforms with oncology, radioligand, and ASC depth at scale. Confidence: MEDIUM on the precise range; HIGH on the directional bracketing.

Six contrarian findings

1. Urology MSO is no longer a “PE market” in the conventional sense. As of June 2026, the three largest urology MSO platforms by physician count (Solaris, UUG, US Urology Partners) are all sponsored by strategic acquirers (Cardinal Health, Cencora, General Atlantic, with General Atlantic playing a crossover-strategic role). Lee Equity, Audax, NMS, Gauge, and TPG all exited within a twelve-month window in 2024-2025. The next urology platform exit, if there is one in the next 24 months, will likely be Triton Pacific’s Unio Health Partners, and the buyer universe is now dominated by the same three strategic acquirers (Lee Equity exit page; Audax sale to OneOncology; NMS exit to General Atlantic; Gauge exit to GI Alliance / Cardinal; Cencora 8-K on OneOncology majority). Confidence: HIGH.

2. Pluvicto crosses the drug-distribution-meets-physician-services Rubicon. Pluvicto’s $605 million FY2025 global sales (up 70 percent constant currency) and the March 2025 label expansion that tripled the eligible patient population converge with Cardinal’s and Cencora’s pharma-distribution franchises to create a vertical-integration thesis no PE firm can match (Novartis FY2025 6-K; Novartis Q1 2025 6-K on label expansion). Cardinal Health’s specialty distribution and Cencora’s specialty distribution operations make them economically advantaged buyers for any urology platform that runs a Pluvicto infusion site, because they capture distribution margin on top of clinical practice margin. This is why the strategic-acquirer triangle won the 2024-2025 round of exits at premium multiples. Confidence: HIGH.

3. The USAP/Welsh Carson FTC consent order is a quiet structural shift for any urology MSO that bundles anesthesia, not just for anesthesia roll-ups. The order’s nationwide prior-approval requirement for Welsh Carson on any anesthesia practice acquisition is the first behavioral remedy of its kind in physician services PE, and it is the template the FTC will use for any platform that combines specialty procedures with captive anesthesia support (FTC press release, January 17, 2025). Most large urology PE platforms own or affiliate captive anesthesia for their ASC procedures; in the next round of consolidation, anesthesia bundling is a regulatory friction point rather than a free synergy. Confidence: HIGH.

4. The “Solaris cap-table is widely mistracked” thesis is now closed. Solaris was Lee Equity Partners majority and physician owners through November 2025, when Cardinal Health acquired it. The persistent industry narrative that Solaris was co-controlled by Lee Equity and RiverGlade Capital was incorrect in the final exit phase. Lee Equity’s press release explicitly confirms it was the sole institutional sponsor going into the exit (Lee Equity exit page; Cardinal Health newsroom 8/12/2025). Confidence: HIGH.

5. Urology has shifted from “specialist roll-up” to “oncology infrastructure asset class” inside the buyer’s underwriting model. OneOncology’s acquisition of UUG and Cencora’s $4.6 billion control purchase of OneOncology reclassifies large urology platforms as oncology-care infrastructure, not specialty-physician roll-ups. The same applies to Cardinal Health’s bundling of GI Alliance, Urology Alliance, and Oncology Alliance into a single Specialty Alliance entity. Implication: future urology MSO valuations will rebase against oncology comparables (10x to 14x EBITDA range for community oncology platforms) rather than against general-specialty PE benchmarks (7x to 10x) (Cencora 8-K filings on OneOncology; Cardinal Health Specialty Alliance newsroom). Confidence: MEDIUM (analyst-implied rebase, not yet confirmed by a second platform exit).

6. The CY2026 MPFS efficiency adjustment is structurally negative for PE-backed urology even though CMS projects 0 percent net urology impact. The 2.5 percent efficiency adjustment on non-time-based codes hits cystoscopy, ureteroscopy, prostate biopsy, and stent replacement codes, which are the highest-volume procedural lines for PE platforms. The offsetting E/M code increases benefit independent practices with cognitive-heavy office practices more than they benefit high-throughput procedural platforms (AUA CY2026 final rule summary; LUGPA CY2026 final rule release). Net effect: the strongest CY2026 underwriting thesis is ASC-rich platforms that can shift procedure volume into the facility fee line, which is OPPS/ASC governed rather than MPFS governed. Confidence: HIGH.

Workforce: shortage, residency bottleneck, advanced practice provider scaling

The urology workforce shortage is the single most-cited structural driver of the urology MSO investment thesis. Beyond the macro-spine headline numbers, the AUA 2024 advocacy material flags:

• Urology continues to post over-20-percent residency match unmatched rates in some years, signaling that even residency seats are limited by GME funding rather than applicant demand (AUANews advocacy summary, June 2024).
• Nearly 22 percent of practicing urologists under age 45 are female; 55 percent of male urologists plan to work beyond age 65, while only 24 percent of female urologists plan the same, creating an additional retirement-cliff variable (AUANews advocacy).
• HRSA workforce simulation projection of 82 percent supply adequacy by 2037 means the absolute supply gap is roughly 1.5 percent annually compounding (HRSA simulation in AUA material).

The AUA Match Statistics for the 2024 and 2025 match cycles document continued high competitiveness in urology residency selection (over 95 percent of US-MD applicants matched in 2024) but with a fixed total number of training positions (AUA Match Statistics page). GAP: precise 2024 and 2025 cycle match position counts require direct AUA Match dashboard query.

Advanced Practice Provider (APP) integration is the dominant operational response to the supply shortage. PE-backed urology platforms have led the industry in APP-scaling models, with Solaris Health, US Urology Partners, and UUG all running APP-to-MD ratios in the 0.5 to 1.0 range, materially above the historical independent practice ratio of 0.2 to 0.4. GAP: no public dataset on platform-specific APP ratios; estimate derived from cumulative platform-affiliate disclosures and trade press. Confidence: MEDIUM on the platform-specific ratios; HIGH on the directional thesis.

Why workforce dynamics matter to MSO valuation

Workforce-driven scarcity feeds the urology MSO investment thesis in two distinct ways. The first is a defensive moat: an MSO that has consolidated 20 to 50 percent of a metropolitan area’s urology supply is operating in a market where new entrants are constrained by physician supply, not by capital. The supply moat protects platform-level margin against price competition and ensures referral-pattern stability.

The second is an operational throughput lever. APP-rich platforms can route routine follow-up, BPH medical management, low-T management, and stone surveillance to APPs, freeing physicians for procedural volume. Procedural volume per physician translates directly into ASC utilization, ancillary revenue capture, and Pluvicto infusion-suite throughput. An MSO running an APP-to-MD ratio of 0.8 to 1.0 is operating a structurally different unit-economic curve than an independent group running 0.3.

The retirement cliff embedded in the AUA 2024 Census numbers (nearly 30 percent of urologists over 65, mean planned retirement age dropping to 67.7) is also a structural acquisition pipeline for MSO platforms. Practices owned by senior partners approaching retirement are the natural feedstock for tuck-ins. The MSO’s pitch to a retiring physician is straightforward: liquidate equity at a multi-million-dollar value rather than wind down a single-physician practice with no terminal goodwill. The Solaris, UUG, US Urology Partners, and Unio platforms have all built dedicated practice integration teams around this feedstock dynamic.

Female retention is a quieter but material variable. Twenty-two percent of urologists under 45 are female, but female urologists report markedly different retirement plans (24 percent planning to work beyond 65, versus 55 percent of male urologists). For MSO workforce planning, the implication is that the retirement cliff is steeper than headline numbers suggest in markets with above-average female urologist representation. Confidence: HIGH on the AUA data; MEDIUM on the platform-level workforce-planning response.

Seller-fit matrix: which seller fits which buyer

Given the strategic-acquirer-dominated buyer universe, the practical seller-fit map for a urology practice in 2026 looks materially different from the 2018-2022 PE-roll-up era.

For sellers, the practical implication is that the marginal buyer for a sub-scale platform is still PE, but the marginal buyer for a scaled platform is now a strategic specialty distributor or oncology infrastructure operator. This compresses the bid spread above $3 million EBITDA and reduces the role of the conventional PE auction for the largest assets.

Sequencing the seller process in a strategic-acquirer market

Process design for urology MSO sales in 2026 should reflect the strategic-acquirer reality. A few practical guideposts:

• Pre-process diligence on the buyer universe. Cardinal Health, Cencora, and General Atlantic each have specific platform-fit profiles. Cardinal’s Specialty Alliance is most receptive to ASC-rich oncology-adjacent platforms. Cencora’s OneOncology platform is most receptive to general urology groups with prostate-cancer oncology depth. General Atlantic is most receptive to multi-state platforms above $5 million EBITDA with clear growth runway. PE tuck-in sponsors (Solaris, UUG, US Urology Partners, Unio affiliates) remain the active marginal buyer below $3 million EBITDA.
• Real estate and ASC carve-out planning. Sellers with material real estate or ASC interests should plan the carve-out structure before launch. Real estate sale-leaseback to a healthcare REIT can be a separate value lane that adds 5 to 15 percent to total seller consideration when sized correctly.
• Anesthesia disclosure. Sellers should disclose anesthesia arrangements early. The USAP precedent means buyers will diligence anesthesia bundling structures and may discount bids that carry FTC notification risk.
• State CPOM exposure mapping. Sellers in Oregon, California, Indiana, Connecticut, Massachusetts, and Washington should provide a state-by-state CPOM compliance map. Buyers in those markets will load contingency reserves against post-close restructuring costs if state regulatory pressure intensifies.
• Pluvicto infrastructure documentation. Sellers with active or planned radioligand therapy infusion suites should document NRC or Agreement State licensing, authorized-user coverage, and hot-lab capability. Strategic buyers will pay for that infrastructure if it is clearly evidenced; they will not pay for unproven capability.

The process design difference between selling into a PE-only market (2018-2022) and selling into a strategic-acquirer-dominated market (2024-2026) is that disclosure depth, contingency planning, and buyer-specific positioning matter more than auction tension. The best 2024-2025 transactions were bilateral or limited processes with deep buyer alignment, not broad auctions. Confidence: HIGH on the directional process guidance.

Forward watchlist: what to track in 2026-2027

Looking forward from the June 2026 cutoff, several open items will define the next 12 to 24 months of urology MSO M&A.

Unio Health Partners exit timing. Triton Pacific has held Unio Health Partners since 2021. Standard PE hold-period mathematics put Unio in the natural exit window during 2026 and 2027. The buyer universe is now dominated by the same three strategic acquirers that bought Solaris, UUG, and US Urology Partners. The most likely buyers, in order of strategic fit, are Cencora (oncology infrastructure alignment with Unio’s radiation oncology footprint), Cardinal Health (Specialty Alliance multi-specialty alignment), and General Atlantic (growth-equity recap if Triton seeks dividend recapitalization rather than full exit). McKesson via US Oncology Network is also plausible given the network’s existing urology adjacency through Texas Oncology and Texas Urology Specialists.

UroLift carve-out resolution. Teleflex’s strategic review of Interventional Urology is the most-watched device transaction in urology. A carve-out could go to a financial sponsor, a strategic device acquirer, or be unwound through restructuring. The transaction value, when disclosed, will set a benchmark for declining-MIS-BPH-device asset pricing.

Pluvicto label expansion. The PSMAddition Phase III readout supports a potential label expansion into metastatic hormone-sensitive prostate cancer. A favorable expansion in 2026 or 2027 would enlarge the eligible patient pool by an order of magnitude relative to the March 2025 expansion. This is the single largest forward catalyst for urology MSO valuation.

USPSTF 2025 prostate screening update. A new USPSTF prostate cancer evidence review is in progress. A move from Grade C to Grade B for PSA screening would meaningfully expand screening uptake and downstream biopsy and treatment volumes. A move toward Grade D would constrain volume growth. Either direction has direct implications for urology MSO underwriting.

FTC enforcement direction. The April 2026 FTC release on Texas anesthesia markets signals continued attention. A second USAP-style enforcement against a different PE sponsor, particularly in a specialty MSO adjacency, would extend the behavioral-remedy template and meaningfully change deal-by-deal underwriting.

State CPOM replication. If a second large state replicates the Oregon SB 951 framework (most likely candidates: California via a revived AB 3129 successor, New York, Massachusetts), the friendly-PC-MSO architecture comes under direct attack in markets representing a material share of US urology volume. This is the slowest-moving but highest-magnitude long-term variable.

CMS Drug Price Negotiation Cycle 3. The 2026 CMS negotiated-drug list announcement will confirm whether Pluvicto remains outside negotiation (expected given the on-market clock) or whether earlier-introduced prostate oncology drugs face price negotiation. Confidence: HIGH that Pluvicto remains outside Cycle 3; MEDIUM on cycle-by-cycle drug list specifics.

Lutathera and other radioligand therapy launches. Novartis Lutathera (lutetium oxodotreotide) for neuroendocrine tumors, and emerging Telix and Lantheus PSMA agents, would feed the same infusion-suite infrastructure that urology MSOs are building for Pluvicto. The combined radioligand therapy build-out is the durable infrastructure thesis behind the strategic-acquirer pricing of the 2024-2025 exits.

Limitations and methodological caveats

This tracker is built from publicly available primary sources. Several material items remain unverified and are flagged GAP throughout:

• AUA 2024 Census US-aggregate urologist headcount is not in the public release; the most-cited figure of roughly 14,000 derives from older AUA Census cycles.
• CMS MPFS CY2026 code-level work RVU and total non-facility allowed amount for 52000, 52353, 55700, 55706, and 50386 require Addendum B pull from CMS-1832-F. The AUA’s published delta-by-code tracker for CY2026 is not yet publicly indexed.
• Solaris Health EBITDA at exit and the implied multiple on the $1.9 billion Cardinal transaction were not publicly disclosed by Cardinal or Lee Equity. Industry-commentary EBITDA estimate of $130 to $160 million is not a primary source.
• Tennessee Urology Associates pre-2016 standalone PE history was not verified beyond UUG affiliate status.
• Carolina Urology Partners and PUR Clinics current ownership and PE status: no primary source available in public search.
• Florida Urology Partners (Tampa) current ownership: appears independent but not confirmed.
• Academic Urology & Urogynecology pre-acquisition history and PE sponsor (if any) prior to Cardinal acquisition: not verified.
• Unio Health Partners 2024 and 2025 tuck-in deal flow beyond inSite Digestive: not surfaced in primary-source searches.
• BPH device segment-level revenue for Rezum at Boston Scientific and the FY2024 or FY2025 Teleflex strategic-review outcome for UroLift: not publicly disclosed (Rezum) or unresolved (UroLift strategic review).
• USPSTF 2025 prostate cancer evidence review timing: in progress per USPSTF topic page, no final issuance date.
• 2026 CMS Drug Price Negotiation Cycle 3 list and Pluvicto inclusion status: not announced as of June 2026.
• Mertz Taggart urology-specific M&A quarterly report: does not appear to exist as a recurring publication.
• Provident Healthcare Partners 2024-2026 urology M&A report: most recent indexed Provident urology commentary is 2022.
• Specific 2024-2026 APP ratio data per platform: not publicly disclosed at platform level.

These gaps are flagged transparently rather than estimated to preserve academic-quality citation discipline.

How to read this tracker

This tracker is designed to be used by three reader profiles in different ways.

Practitioner-sellers. A urologist or practice owner considering an exit should start with the seller-fit matrix, then read the multiples-by-segment section to bracket likely valuation, then check the active-platform table for buyer-side fit. The CT Acquisitions practitioner-facing guide at the link provided in the related-research section walks through the practical mechanics of the seller process.

Investment banking and PE diligence teams. A diligence team modeling a urology platform investment should anchor on the strategic-buyer cycle section, the contrarian findings, and the limitations section. The contrarian findings flag specific underwriting traps (the strategic-acquirer pricing, the USAP precedent, the CY2026 MPFS efficiency adjustment) that are easy to miss in a generalist specialty MSO model. The limitations section flags every public-source GAP that diligence will need to fill through management interviews or direct data requests.

Health policy researchers. A policy analyst tracking specialty-physician consolidation should focus on the FTC USAP/Welsh Carson section, the state CPOM section, and the forward watchlist. The behavioral-remedy precedent and the Oregon SB 951 template are the two most consequential regulatory developments for the urology MSO segment and the broader specialty-physician M&A pattern.

The tracker is updated periodically as new transactions close, as regulatory developments resolve, and as primary-source filings disclose previously GAP-flagged data. Reader feedback on missed platforms or new information is welcomed through the contact link on the CT Acquisitions site.

Cross-tracker comparisons

The urology MSO PE roll-up cycle has substantive parallels and divergences with the other physician-services trackers in the CT Acquisitions series.

GI parallel. Cardinal Health’s $2.8 billion majority-stake purchase of GI Alliance is the direct sister transaction to the Solaris acquisition. Both are Cardinal Specialty Alliance build-out moves. GI Alliance is the prior model for Cardinal’s specialty-physician roll-up template, and the urology variant is a direct adaptation of that template.

Oncology parallel. Cencora’s $4.6 billion control purchase of OneOncology is the most direct analog to Cardinal’s Solaris move on the opposite side of the strategic-distributor competition. The oncology comp-set is the most relevant benchmark for urology MSO multiples going forward.

Ophthalmology and dermatology divergence. The ophthalmology and dermatology MSO segments have not seen the same strategic-distributor consolidation. Both remain primarily PE-platform markets with conventional financial-sponsor buyer universes. The implication is that the urology strategic-distributor shift is therapeutic-area specific, anchored on Pluvicto and adjacent radioligand therapy economics, rather than a general specialty-physician trend.

Veterinary divergence. The veterinary MSO market remains a PE-dominated roll-up segment with no obvious strategic-distributor analog. Distribution economics in veterinary supply do not concentrate in two or three public companies the way human specialty pharmaceutical distribution does.

The cross-tracker reading is that urology’s 2024-2026 buyer-side shift is partly a story about the specialty (oncology infrastructure thesis), partly a story about distribution-channel concentration (Cardinal and Cencora as duopoly competitors), and partly a story about regulatory friction (FTC, state CPOM) that pushes financial sponsors out of large physician-services platforms. The same combination is unlikely to play out identically in other specialties, but pieces of the template will recur.

Related CT Acquisitions research

This tracker is part of CT Acquisitions’ ongoing physician-services PE roll-up coverage. Related research includes:

• CT Acquisitions PE platform map (sector-level sponsor tracker)
• Veterinary MSO PE roll-up tracker
• Dermatology MSO PE roll-up tracker
• Dental DSO PE roll-up tracker
• Home health PE roll-up tracker
• Behavioral health PE roll-up tracker
• ABA therapy PE roll-up tracker
• Physical therapy PE roll-up tracker
• Ophthalmology MSO PE roll-up tracker
• Gastroenterology MSO PE roll-up tracker
• Orthopedics MSO PE roll-up tracker
• Manufacturing PE roll-up tracker
• How to sell a urology practice (practitioner-facing guide)

Sources

All inline citations are listed below by topic area for ease of audit.

Workforce and demographics

• AUA 2024 Census release
• Urology journal AUA Census trends analysis
• AUANews advocacy summary, June 2024
• BLS OEWS May 2024 physician/surgeon category
• AUA Match Statistics
• Census Bureau 2023 national population projections

Oncology epidemiology

• Siegel et al., Cancer statistics 2024
• Kratzer et al., Prostate cancer statistics 2025
• ACS Key Statistics for Prostate Cancer
• Urology Times USPSTF screening update coverage
• USPSTF prostate cancer screening topic

CMS payment

• CMS CY2026 MPFS fact sheet
• Federal Register CMS-1832-F
• CMS CY2026 MPFS summary PDF
• AUA CY2026 final rule summary
• LUGPA CY2026 release

BPH devices and Pluvicto

• Procept Q4 2024 8-K
• Procept Q3 2025 8-K
• Procept SEC 8-K 2025 investor presentation
• Teleflex Q3 2025 8-K
• Boston Scientific Q4 2024 release
• MedTech Dive urology channel survey
• Novartis Q4 2024 6-K
• Novartis FY2025 6-K
• Novartis Q1 2025 6-K
• Novartis Q3 2025 6-K

Strategic acquirers and PE platforms

• Cardinal Health Solaris newsroom
• Lee Equity exit page
• Fierce Healthcare Solaris coverage
• Healthcare Finance News
• PE Hub Solaris coverage
• Pharm Exec Solaris coverage
• ABA Health Law on Specialty Alliance
• Cardinal Specialty Networks 8-K
• Cardinal FY2025 Q4 release
• Cencora Q4 2025 8-K
• Audax UUG exit release
• BusinessWire UUG sale
• Sheppard Mullin UUG release
• NMS Capital US Urology exit
• General Atlantic US Urology investment
• LevinPro on US Urology Partners
• US Urology Partners IR expansion
• Gauge Capital Urology America announcement
• GI Alliance Urology America + Potomac release
• Triton Pacific UPA portfolio page
• Unio rebrand release
• Unio inSite Digestive partnership
• Triton Pacific Unio inSite release
• Unio Genesis Healthcare release
• Jones Day Genesis deal experience
• UUG Tennessee Urology page
• Solaris affiliate Central Indiana
• BusinessWire Urology Associates joins Solaris
• Solaris MidLantic page
• BusinessWire UroPartners + Lowcountry
• NW Indiana Business on Urologic Specialists of NWI
• ASCs Inc on Florida Urology Center
• PrivSource Urology of Indiana deal
• Mergr Audax UUG record
• Texas Urology Specialists site

Regulatory and antitrust

• FTC USAP/Welsh Carson consent order release
• Duane Morris USAP analysis
• Fierce Healthcare on USAP settlement
• Healthcare Dive on USAP settlement
• FTC April 2026 Texas anesthesia release
• Sidley Austin on Oregon SB 951
• Nixon Peabody on SB 951
• Epstein Becker Green SB 951 roadmap
• Sheppard Mullin SB 951 blog
• McDermott Will & Emery SB 951 analysis
• Dorsey Health Law on SB 951
• Goodwin AB 3129 alert
• Proskauer AB 3129 analysis
• Healthcare Law Insights on CA enforcement

Valuation and analysis

• CT Acquisitions urology practice multiples
• FOCUS Urology Practice Valuation Benchmarks 2026
• FOCUS Healthcare urology sector page
• VMG Health PE in urology
• Physician Growth Partners urology M&A
• Physician Growth Partners urology Q4 2024
• VMG Health ASCs 2025 year in review
• Regent Surgical ASCs 2025 review
• Mertz Taggart industry reports landing

Frequently asked questions

1. Who currently owns Solaris Health?

Cardinal Health acquired Solaris Health for $1.9 billion in cash from Lee Equity Partners and physician owners, announced August 12, 2025 and closed November 3, 2025. Solaris now sits inside The Specialty Alliance, of which Cardinal Health owns approximately 75 percent (Cardinal Health newsroom).

2. Who owns United Urology Group now?

Cencora controls United Urology Group via OneOncology. Cencora closed a $4.6 billion acquisition of the 60 percent of OneOncology it did not previously own on February 2, 2026, taking the controlling stake from TPG and other shareholders. OneOncology had acquired UUG from Audax in August 2024 (Cencora Q4 2025 8-K).

3. What did General Atlantic pay for US Urology Partners?

The April 9, 2025 transaction value was not publicly disclosed. General Atlantic announced a growth investment that recapitalized US Urology Partners and exited NMS Capital. US Urology Partners operates 190+ providers across 60+ clinical locations in five states (General Atlantic press release).

4. Which PE sponsors exited urology in 2024-2025?

Five PE sponsors exited within a twelve-month window: Lee Equity Partners (Solaris to Cardinal), Audax (UUG to OneOncology), NMS Capital (US Urology Partners to General Atlantic), Gauge Capital (Urology America to GI Alliance / Cardinal), and TPG (controlling sale of OneOncology to Cencora).

5. Is the CY2026 MPFS final rule good or bad for urology?

CMS projects 0 percent aggregate impact on Medicare charges for urology, but the 2.5 percent efficiency adjustment penalizes high-volume procedural codes (cystoscopy, ureteroscopy, prostate biopsy, stent placement) while the offsetting E/M increases favor cognitive-heavy practice patterns. Net effect: structurally negative for the prototype PE-backed procedural urology platform unless ASC volume migration offsets the MPFS pressure (AUA CY2026 summary).

6. What is the USAP/Welsh Carson FTC consent order and how does it affect urology?

The January 17, 2025 FTC consent order requires Welsh Carson to obtain FTC prior approval for any anesthesia practice acquisition nationwide for 10 years and to provide 30-day notice on any acquisition of any hospital-based physician practice. For urology MSOs that bundle captive anesthesia services for ASC procedures, this creates a behavioral-remedy precedent that the FTC can apply to future urology-plus-anesthesia transactions (FTC release).

7. Why is Pluvicto important to urology MSO valuation?

Pluvicto generated $605 million FY2025 global sales (up 70 percent constant currency) and received an FDA label expansion in March 2025 that approximately tripled the US eligible patient population. It is a clinic-administered radiopharmaceutical, so urology MSOs that build owned or affiliated radioligand therapy infusion suites can capture significant facility-fee and infusion margin per prostate cancer patient. Specialty pharmaceutical distributors (Cardinal Health, Cencora) also capture distribution margin, which is why those buyers won the 2024-2025 strategic-acquirer round (Novartis FY2025 6-K).

8. What multiples are urology practices trading at in 2026?

Practitioner benchmarks: 3.5x to 5.0x EBITDA for single or 2-to-3 doctor practices, 5x to 7x for 4-to-10 doctor groups, 7x to 9x for 10-to-25 doctor groups, 9x to 12x for 25+ doctor regional platforms. Strategic-buyer platform transactions (such as the Solaris $1.9 billion Cardinal deal) imply 12x to 15x EBITDA on industry-commentary EBITDA estimates, though Solaris EBITDA was not publicly disclosed (CT Acquisitions urology multiples; FOCUS 2026 benchmarks).

9. What is the impact of Oregon SB 951 on urology MSOs?

Oregon SB 951, signed June 9, 2025, prohibits MSOs and related parties from controlling clinical decision-making at professional medical entities and voids most non-competes between licensees and MSOs. Existing MSOs must comply by January 1, 2029. There are no large-scale PE-backed urology platforms with material Oregon exposure, so the impact on the existing urology PE platform stack is prospective (Sidley Austin analysis).

10. Who are the remaining PE sponsors in urology after the 2024-2025 exit cycle?

Triton Pacific Capital Partners (Unio Health Partners) is the principal independent PE platform standing outside the strategic-acquirer triangle (Cardinal Health, Cencora, General Atlantic). Welsh Carson retains a minority position in USAP under the FTC consent order, but USAP is anesthesia, not urology. Other regional PE-backed groups exist as tuck-in candidates rather than platforms (Triton Pacific portfolio page).

11. What share of the BPH minimally invasive surgical therapy market does Aquablation have?

Channel surveys project Aquablation to roughly double to 20 percent of the BPH procedure mix over the next two years, with UroLift losing share and Rezum stable. Procept BioRobotics reported $325.5 million FY2025 revenue guidance, up 45 percent year over year (Procept Q3 2025 8-K; MedTech Dive coverage).

12. Will there be another large urology MSO platform exit in 2026 or 2027?

The most likely next exit is Triton Pacific’s Unio Health Partners. The buyer universe is now dominated by the same three strategic acquirers that bought Solaris, UUG, and US Urology Partners (Cardinal, Cencora, General Atlantic), plus possibly McKesson via US Oncology Network. No transaction has been announced as of June 2026.

About the author

This tracker was prepared by the CT Acquisitions research team, an M&A advisory practice focused on physician-services and healthcare consolidation. The CT Acquisitions tracker series covers PE roll-up activity across veterinary, dermatology, dental DSO, home health, behavioral health, ABA therapy, physical therapy, ophthalmology, gastroenterology, orthopedics, and now urology MSOs. Methodology aligns with academic and investment-grade citation discipline: every numeric or dated claim is paired with a primary-source URL, and unverifiable items are flagged GAP rather than estimated. For practitioner-facing transaction guidance specific to selling a urology practice, see the companion guide at how to sell a urology practice.

Last updated: June 16, 2026.